The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor β signaling

Arthritis and Rheumatology

Volumn 67, Issue 5, 2015, Pages 1323-1334

  Wei, Jun ^a   Ghosh, Archit K ^a   Chu, Haiyan ^b   Fang, Feng ^a   Hinchcliff, Monique E ^a   Wang, Jiucun ^b   Marangoni, Roberta Goncalves ^a   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; E1A ASSOCIATED P300 PROTEIN; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; SIRTUIN 1; SIRTUIN 6; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; ENZYME INHIBITOR; HISTONE ACETYLTRANSFERASE PCAF; P300-CBP-ASSOCIATED FACTOR; RESVERATROL; SMAD PROTEIN; STILBENE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL HYPOXIA; CELL LEVEL; CELL MIGRATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME REGULATION; ENZYME REPRESSION; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RNA ANALYSIS; SCORING SYSTEM; SIGNAL TRANSDUCTION; SKIN CULTURE; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TISSUE LEVEL; UPREGULATION; WOUND HEALING; ANIMAL; CASE CONTROL STUDY; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; FIBROBLAST; GENETICS; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; SKIN;

ANIMALS; CASE-CONTROL STUDIES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; MICE; P300-CBP TRANSCRIPTION FACTORS; PLATELET-DERIVED GROWTH FACTOR; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SIRTUIN 1; SKIN; SMAD PROTEINS; STILBENES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84928641974     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39061     Document Type: Article

References (52)

1. Bhattacharyya S, Wei J, Varga J., Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2012; 8: 42-54.
2. Ghosh AK, Varga J., The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol 2007; 213: 663-71.
3. Mann J, Mann DA., Epigenetic regulation of wound healing and fibrosis. Curr Opin Rheumatol 2013; 25: 101-7.
4. Ghosh AK, Bhattacharyya S, Lafyatis R, Farina G, Yu J, Thimmapaya B, et al. p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β epigenetic feed-forward amplification of fibrosis. J Invest Dermatol 2013; 133: 1302-10.
5. Ghosh AK., FAT-free p300 is good for scar-free tissue repair. J Cell Biochem 2014; 115: 1486-9.
6. Bhattacharyya S, Ghosh AK, Pannu J, Mori Y, Takagawa S, Chen G, et al. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor β. Arthritis Rheum 2005; 52: 1248-58.
7. Hubbard BP, Sinclair DA., Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 2014; 35: 146-54.
8. Dokmanovic M, Clarke C, Marks PA., Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5: 981-9.
9. Das C, Lucia MS, Hansen KC, Tyler JK., CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 2009; 459: 113-7.
10. Kong S, Kim SJ, Sandal B, Lee SM, Gao B, Zhang DD, et al. The type III histone deacetylase Sirt1 protein suppresses p300-mediated histone H3 lysine 56 acetylation at Bclaf1 promoter to inhibit T cell activation. J Biol Chem 2011; 286: 16967-75.
11. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-63.
12. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
13. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PloS One 2008; 3: e2696.
14. Hinchcliff M, Huang CC, Wood TA, Mahoney JM, Martyanov V, Bhattacharyya S, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 2013; 133: 1979-89.
15. Wei J, Zhu H, Komura K, Lord G, Tomcik M, Wang W, et al. A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses. Ann Rheum Dis 2014; 73: 446-54.
16. Lakos G, Takagawa S, Chen SJ, Ferreira AM, Han G, Masuda K, et al. Targeted disruption of TGF-β/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004; 65: 203-17.
17. Zhang J, Lee SM, Shannon S, Gao B, Chen W, Chen A, et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 2009; 119: 3048-58.
18. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998; 1: 611-7.
19. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, et al. Peroxisome proliferator-activated receptor-γ abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 2009; 23: 2968-77.
20. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
21. Torres G, Frisella PD, Yousuf SJ, Sarwar S, Baldinger L, Zakhary SM, et al. A ChIP-cloning approach linking SIRT1 to transcriptional modification of DNA targets. Biotechniques 2008; 44: Pxii-Pxiv.
22. Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L., Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev 2006; 20: 1075-80.
23. Csiszar A, Labinskyy N, Pinto JT, Ballabh P, Zhang H, Losonczy G, et al. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 2009; 297: H13-20.
24. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013; 339: 1216-9.
25. Dasgupta B, Milbrandt J., Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A 2007; 104: 7217-22.
26. Ghosh AK, Yuan W, Mori Y, Varga J., Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-β involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene 2000; 19: 3546-55.
27. Mori Y, Chen SJ, Varga J., Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003; 48: 1964-78.
28. Jinnin M, Ihn H, Mimura Y, Asano Y, Tamaki K., Involvement of the constitutive complex formation of c-Ski/SnoN with Smads in the impaired negative feedback regulation of transforming growth factor β signaling in scleroderma fibroblasts. Arthritis Rheum 2007; 56: 1694-705.
29. Altorok N, Almeshal N, Wang Y, Kahaleh B., Epigenetics, the holy grail in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2014. E-pub ahead of print.
30. Shahbazian MD, Grunstein M., Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007; 76: 75-100.
31. Hall JA, Dominy JE, Lee Y, Puigserver P., The sirtuin family's role in aging and age-associated pathologies. J Clin Invest 2013; 123: 973-9.
32. Guarente L., Sirtuins, aging, and metabolism. Cold Spring Harb Symp Quant Biol 2011; 76: 81-90.
33. Sequeira J, Boily G, Bazinet S, Saliba S, He X, Jardine K, et al. sirt1-null mice develop an autoimmune-like condition. Exp Cell Res 2008; 314: 3069-74.
34. Suwa M, Nakano H, Radak Z, Kumagai S., Endurance exercise increases the SIRT1 and peroxisome proliferator-activated receptor γ coactivator-1α protein expressions in rat skeletal muscle. Metabolism 2008; 57: 986-98.
35. Zerr P, Palumbo-Zerr K, Huang J, Tomcik M, Sumova B, Distler O, et al. Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis. Ann Rheum Dis 2014. E-pub ahead of print.
36. Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ., Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PloS One 2012; 7: e42357.
37. Herskovits AZ, Guarente L., SIRT1 in neurodevelopment and brain senescence. Neuron 2014; 81: 471-83.
38. Chang HC, Guarente L., SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab 2014; 25: 138-45.
39. Vasko R, Xavier S, Chen J, Lin CH, Ratliff B, Rabadi M, et al. Endothelial sirtuin 1 deficiency perpetrates nephrosclerosis through downregulation of matrix metalloproteinase-14: relevance to fibrosis of vascular senescence. J Am Soc Nephrol 2014; 25: 276-91.
40. Di Pascoli M, Divi M, Rodriguez-Vilarrupla A, Rosado E, Gracia-Sancho J, Vilaseca M, et al. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol 2013; 58: 904-10.
41. Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, Periasamy M, Gupta M., Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2010; 298: H833-43.
42. Li J, Qu X, Ricardo SD, Bertram JF, Nikolic-Paterson DJ., Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am J Pathol 2010; 177: 1065-71.
43. Akgedik R, Akgedik S, Karamanli H, Uysal S, Bozkurt B, Ozol D, et al. Effect of resveratrol on treatment of bleomycin-induced pulmonary fibrosis in rats. Inflammation 2012; 35: 1732-41.
44. Sun L, Li H, Chen J, Iwasaki Y, Kubota T, Matsuoka M, et al. PIASy mediates hypoxia-induced SIRT1 transcriptional repression and epithelial-to-mesenchymal transition in ovarian cancer cells. J Cell Sci 2013; 126: 3939-47.
45. Simic P, Williams EO, Bell EL, Gong JJ, Bonkowski M, Guarente L., SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep 2013; 3: 1175-86.
46. Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 2012; 31: 4619-29.
47. Ponnusamy M, Zhou X, Yan Y, Tang J, Tolbert E, Zhao TC, et al. Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy. J Pharmacol Exp Ther 2014; 350: 243-56.
48. Mortuza R, Chen S, Feng B, Sen S, Chakrabarti S., High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway. PLoS One 2013; 8: e54514.
49. Chen Y, Zhao W, Yang JS, Cheng Z, Luo H, Lu Z, et al. Quantitative acetylome analysis reveals the roles of SIRT1 in regulating diverse substrates and cellular pathways. Mol Cell Proteomics 2012; 11: 1048-62.
50. Kuno A, Hori YS, Hosoda R, Tanno M, Miura T, Shimamoto K, et al. Resveratrol improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of p300 protein. J Biol Chem 2013; 288: 5963-72.
51. Huang XZ, Wen D, Zhang M, Xie Q, Ma L, Guan Y, et al. Sirt1 activation ameliorates renal fibrosis by inhibiting the TGF-β/Smad3 pathway. J Cell Biochem 2014; 115: 996-1005.
52. Lakota K, Wei J, Carns M, Hinchcliff M, Lee J, Whitfield ML, et al. Levels of adiponectin, a marker for PPAR-γ activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? Arthritis Res Ther 2012; 14: R102.